TABLE 5.
Summary of descriptive statistics of ABX464-NGlc PK parameters after the fourth oral administration of 50 mg ABX464 under fed and fasted conditions (day 10) in group 2 subjectsa
| Condition and/or value | Cmax (ng/ml) | Tmaxb (h) | AUC0–t (ng · h/ml) | AUC0–∞ (ng · h/ml) | t1/2 (h) |
|---|---|---|---|---|---|
| Fasted | n = 12 | n = 12 | n = 12 | n = 12 | n = 12 |
| Mean | 2,314.25 | 4.00 | 244,319.92 | 245,171.27 | 101.72 |
| SD | 1,011.19 | 3.00–6.00 | 139,006.91 | 139,224.18 | 29.11 |
| GM | 2,099.95 | 206,875.99 | 207,700.73 | 98.08 | |
| Fed | n = 12 | n = 12 | n = 12 | n = 12 | n = 12 |
| Mean | 3,245.00 | 4.00 | 325,474.37 | 326,237.38 | 101.39 |
| SD | 2,128.91 | 2.62–8.00 | 241,001.77 | 241,212.80 | 20.85 |
| GM | 2,845.01 | 276,156.04 | 276,923.59 | 99.47 | |
| Point estimate | 1.35 | 1.33 | 1.33 | ||
| 90% CI | 0.96–1.91 | 0.88–2.03 | 0.88–2.02 |
a
Cmax, maximum concentration; Tmax, time to maximum concentration; AUC0–t, area under the concentration-time curve from time zero to the time of last quantifiable concentration; AUC0–∞, AUC from time zero to infinity; t1/2, apparent terminal elimination half-life; n, number of subjects; SD, standard deviation; GM, geometric mean; CI, confidence interval.
b
Instead of means and standard deviations, the values given for this parameter are medians and ranges (minimum–maximum), respectively.